WiseGuyReports.com adds "3 D Printing Dental Device Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024" reports to its database. This report provides in depth study of "3 D Printing Dental Device Market" using SWOT analysis i.e. Major Key Points in Table of Content.
Gainers Kandi Technologies Group Inc shares gained 34.34 percent to close at $7.98 on Wednesday after the company reported NHTSA approval of 2 electric vehicle models. Arca Biopharma Inc shares surged 31.27 percent to close at $0.5080 on Wednesday after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support a
ABBOTT PARK- Abbott announced today it has received CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine HBsAg 2 test for use with serum, plasma or whole blood.1, 2,3. In a global effort to reduce the current burden of disease, the World Health Organization has set baseline tar
With this approval, HUMIRA has become the first treatment indicated for HS in Japan, and is now approved for 11 indications in Japan. The approval of this additional indication is based on the data from a Japanese Phase III study and overseas clinical trials. In the clinical trial conducted in Japan, the percentage of patients who achieved the prim
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8 th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m....
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE study of plazomicin in a Letter to the Editor. Achaogen's EPIC...
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 EPIC study of ZEMDRI. Wagenlehner, M.D., Director, Clinic for Urology,
SEATTLE- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA Program, which aims to evaluate the effectivenes
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office located at 1777 Sentry Parkway West in Blue Bell, Pa. The approximately 12,000 square-feet office space will serve as.
SAN DIEGO- Adamis Pharmaceuticals Corporation announced today that the article entitled' Higher doses of naloxone are needed in the synthetic opioid era' has been published in the peer reviewed journal Substance Abuse Treatment, Prevention, and Policy. According to statistics published by the Centers for Disease Control and Prevention in 2017, drug
-Adaptiiv Medical Technologies Inc. is pleased to announce that the Centre Hospitalier de l'Universit de Montral has become its latest Collaboration Partner. The Centre Hospitalier de l'Universite de Montreal is an innovative hospital devoted to serving patients. As the Universit de Montral hospital, CHUM is dedicated to care, research, tea
This partnership brings together critical capabilities to allow the commencement of Adial's planned initial Phase 3 trial, with Catalent providing packaging and distribution. Catalent has a robust, global network, with the presence in Europe and the U.S. to provide flexible, integrated clinical supply services for investigational medicinal products
WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024" reports to its database. WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to
-ADVANZ PHARMA Corp., an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with continued access to high quality, niche established medicines, today announced it intends to release its fourth quarter and 2018 financial results before market open on Thursday, March 14, 2
Merck& Co. disclosed Tuesday its cancer drug Keytruda failed a Phase 3 study in advanced liver cancer, less than four months after the immunotherapy gained an accelerated approval for a similar indication. In a statement, Merck Research Laboratories chief medical officer Roy Baynes called the efficacy results "generally consistent with findings fro
MORTSEL, Belgium, Feb. 21, 2019/ PRNewswire/. DR 800* offers one solution for radiography, fluoroscopy, tomography and advanced clinical applications. Tomosynthesis algorithms reconstruct images very quickly. MUSICA? Digital Tomosynthesis software processes the tomographic slices that are synthesized from a single tomographic sweep..
Alembic Pharmaceuticals Limited today announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application Acetazolamide Extended-Release Capsules, 500 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product Diamox Sequels, 500 mg, of Teva Branded Pharmaceutical...
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019/ PRNewswire/ Amgen, Cytokinetics, Incorporated and Servier today announced that METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potenti
WESTMINSTER- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design of a pivotal Phase 3 clinical..
WiseGuyReports.com adds Assisted Living Software Market 2019 Global Analysis and Opportunities Research Report Forecasting 2025 reports to its database.. PUNE, MAHARASHTRA, INDIA, February 21, 2019/ EINPresswire.com/ Assisted Living Software Market:. Assisted living facilities use software solutions to manage the comfort, security, and sati
California Attorney General Xavier Becerra issued the following news release:. California Attorney General Xavier Becerra and Assemblymember Jim Wood today unveiled legislation to help curb increasing drug prices in California. These agreements, known as "pay-for-delay" agreements, have significantly contributed to price increases for prescription.
A recently compiled report of Fact.MR envisages the global market for automated breast ultrasound system to record a value CAGR of 9.3% over the period of forecast, 2018 to 2027. Over 1,800 units of automated breast ultrasound systems are foreseen to be sold worldwide by 2027- end. Standardized Training Imperative for Radiologists.
Axonics Modulation Technologies, Inc. a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, disclosed today positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the U.S....
NEW YORK- AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today provided a clinical development and strategic corporate update. Key highlights of OPTION include: Primary endpoint is a six-week non-inferiority, coefficient of fat absorption assessment comparing..
First commercial program under Bavarian Nordic and Janssen Vaccines& Prevention B.V. collaboration advancing into clinical trials A therapeutic vaccine may represent a novel approach for early treatment and interception of HPV-induced cancers. COPENHAGEN, Denmark, February 21, 2019- Bavarian Nordic A/S today announced that the first patient has bee